In fact in cancer cells, HSP70 takes a place in many anti-apoptotic pro-survival pathways [51], i.e., HSP70 binds to DR4/5 (death receptor 4 and 5) [52], binds Bax [53], blocks JNK activity [54], stops the recruitment of pro-caspase 9 to the apoptosome [55], prevents the release to the cathepsins [56,57], etc. HSP70 is frequently aberrantly expressed in many solid tumors, as well as hematological malignancies with prognostic and therapeutic implications. The gene discussed is TNFRSF10A; the disease is hematologic disorder.